TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors

Launched by THUNDER BAY REGIONAL HEALTH RESEARCH INSTITUTE · Apr 17, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating two different types of lasers, MOSES Holmium and Thulium Fiber Laser (TFL), to see which one might be better for removing bladder tumors during a procedure called transurethral laser enucleation. The main goal is to find out if there are any differences in outcomes, such as how well the tumors are removed and how patients recover, between the two laser techniques.

To participate in this study, individuals must be at least 18 years old and have been diagnosed with a bladder tumor that can be treated with laser surgery, as determined by a urologist. However, those with more serious conditions, such as certain invasive tumors or other urinary tract tumors, are not eligible. If you join the trial, you will be randomly assigned to receive either the MOSES or TFL laser treatment. The trial is currently recruiting participants, and it welcomes individuals of any gender between the ages of 18 and 74. This research could help improve treatment options for bladder tumors in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Over 18 years of age at the time of enrollment.
• • 2. Patients presented with visual criteria suggesting bladder tumor by outpatient cystoscopy will be legible for inclusion.
• Exclusion Criteria:
• • 1. Tumors deemed not eligible for laser resection as determined by the Urologist e.g. obvious muscle-invasive or metastatic at presentation
• • 2. Synchronous either urethral tumors or upper urinary tract tumor
• • 3. History of Carcinoma in situ
• • 4. Contracted bladder